van Doorn PA - Search Results

1

A clinical prognostic scoring system for Guillain-Barré syndrome.

van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, Jacobs BC. van Koningsveld R, et al. Among authors: van doorn pa. Lancet Neurol. 2007 Jul;6(7):589-94. doi: 10.1016/S1474-4422(07)70130-8. Lancet Neurol. 2007. PMID: 17537676

2

Psychometric evaluation of a new handicap scale in immune-mediated polyneuropathies.

Merkies IS, Schmitz PI, Van Der Meché FG, Samijn JP, Van Doorn PA. Merkies IS, et al. Among authors: van doorn pa, van der meche fg. Muscle Nerve. 2002 Mar;25(3):370-7. doi: 10.1002/mus.10045. Muscle Nerve. 2002. PMID: 11870713

3

Treatment of immune neuropathies.

Van Doorn PA, Garssen MP. Van Doorn PA, et al. Curr Opin Neurol. 2002 Oct;15(5):623-31. doi: 10.1097/00019052-200210000-00014. Curr Opin Neurol. 2002. PMID: 12352007 Review.

4

Screening for anti-ganglioside antibodies in hypocretin-deficient human narcolepsy.

Overeem S, Geleijns K, Garssen MP, Jacobs BC, van Doorn PA, Lammers GJ. Overeem S, et al. Among authors: van doorn pa. Neurosci Lett. 2003 Apr 24;341(1):13-6. doi: 10.1016/s0304-3940(03)00085-5. Neurosci Lett. 2003. PMID: 12676332

5

Anti-GM1 IgG antibodies induce leukocyte effector functions via Fcgamma receptors.

van Sorge NM, van den Berg LH, Geleijns K, van Strijp JA, Jacobs BC, van Doorn PA, Wokke JH, van de Winkel JG, Leusen JH, van der Pol WL. van Sorge NM, et al. Among authors: van der pol wl, van strijp ja, van den berg lh, van doorn pa, van de winkel jg. Ann Neurol. 2003 May;53(5):570-9. doi: 10.1002/ana.10503. Ann Neurol. 2003. PMID: 12730990

6

Comparison between impairment and disability scales in immune-mediated polyneuropathies.

Merkies IS, Schmitz PI, Van Der Meché FG, Van Doorn PA. Merkies IS, et al. Among authors: van doorn pa, van der meche fg. Muscle Nerve. 2003 Jul;28(1):93-100. doi: 10.1002/mus.10410. Muscle Nerve. 2003. PMID: 12811779 Clinical Trial.

7

Chlamydia pneumoniae and the risk for exacerbation in multiple sclerosis patients.

Buljevac D, Verkooyen RP, Jacobs BC, Hop W, van der Zwaan LA, van Doorn PA, Hintzen RQ. Buljevac D, et al. Among authors: van der zwaan la, van doorn pa. Ann Neurol. 2003 Dec;54(6):828-31. doi: 10.1002/ana.10759. Ann Neurol. 2003. PMID: 14681894

8

Immunotherapy for Guillain-Barré syndrome.

van Doorn PA, van Koningsveld R. van Doorn PA, et al. Among authors: van koningsveld r. Lancet Neurol. 2004 Feb;3(2):84. doi: 10.1016/s1474-4422(03)00660-4. Lancet Neurol. 2004. PMID: 14746999 Review. No abstract available.

9

Functional polymorphisms in LPS receptors CD14 and TLR4 are not associated with disease susceptibility or Campylobacter jejuni infection in Guillain-Barré patients.

Geleijns K, Jacobs BC, Van Rijs W, Tio-Gillen AP, Laman JD, van Doorn PA. Geleijns K, et al. Among authors: van rijs w, van doorn pa. J Neuroimmunol. 2004 May;150(1-2):132-8. doi: 10.1016/j.jneuroim.2004.01.003. J Neuroimmunol. 2004. PMID: 15081257

10

Fas polymorphisms are associated with the presence of anti-ganglioside antibodies in Guillain-Barre syndrome.

Geleijns K, Laman JD, van Rijs W, Tio-Gillen AP, Hintzen RQ, van Doorn PA, Jacobs BC. Geleijns K, et al. Among authors: van rijs w, van doorn pa. J Neuroimmunol. 2005 Apr;161(1-2):183-9. doi: 10.1016/j.jneuroim.2004.12.001. J Neuroimmunol. 2005. PMID: 15748958

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

427 results

Search Page

Filters